Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Crum Cianflone, Nancy ^a,b,c   Roediger, Mollie Poehlman ^a,d   Eberly, Lynn ^a,d   Headd, Maryam ^c   Marconi, Vincent ^a,e   Ganesan, Anuradha ^a,f   Weintrob, Amy ^a,f   Barthel, R Vincent ^a,g   Fraser, Susan ^a,h   Agan, Brian K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^h TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT CARE; PREVALENCE; PROSPECTIVE STUDY; SEX DIFFERENCE; UNDERWEIGHT; WEIGHT GAIN; EPIDEMIC; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; EPIDEMICS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77956314910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010106     Document Type: Article

References (40)

1. Parikh NI, Pencina MJ, Wang TJ, Lanier KJ, Fox CS, et al. (2007) Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 120: 242-250.
2. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, et al. (2005) A tale of 2 epidemics. The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 39: 557-561.
3. Campa A, Yang Z, Lai S, Xue L, Phillips JC, et al. (2005) HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 41: 1179-1185.
4. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, et al. (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31: 803-805.
5. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A (2008) Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS 22: 925-930.
6. Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
7. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
8. Smit E, Skolasky RL, Dobs AS, Calhoun BC, Visscher BR, et al. (2002) Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol 156: 211-218.
9. Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, et al. (1999) Changes in AIDS-defining illnesses in a London clinic, 1987-1998. J Acquir Immune Defic Syndr 21: 401-407.
10. Hodgson LM, Ghattas H, Pritchitt H, Schwenk A, Payne L, et al. (2001) Wasting and obesity in HIV outpatients. AIDS 15: 2341-2342.
11. Ferrando SJ, Rabkin JG, Lin SH, McElhiney M (2005) Increase in body cell mass and decrease in wasting are associated with increasing potency of antiretroviral therapy for HIV infection. AIDS Patient Care STDS 19: 216-223.
12. Redfield RR, Wright DC, Tramount ED (1986) The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 314: 131-132.
13. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults; the evidence report (1998) Obes Res 6: 51S-209S.
14. World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization, 1995. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_854.pdf, accessed March 17, 2008.
15. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, et al. (2006) Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care setting. MMWR Recomm Rep 55: 1-17.
16. Centers for Disease Control and Prevention. (2006) State-specific prevalence of obesity among adults-United States, 2005. MMWR Morb Mortal Wkly Rep 2006 55: 985-8.
17. Bray RM, ed. 2005 Department of Defense Survey of Health Related Behaviors Among Active Duty Military Personnel. [report on the Internet] Research Triangle Park: RIT International. Available from: http://dodwws.rti.org/active/index.cfm, accessed March 18, 2009.
18. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C (2005) Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 40: 70-76.
19. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, et al. (1998) Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 18: 80-85.
20. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, et al. (2002) Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 230-236.
21. Palenicek JG, Graham NM, He D, Hoover DA, Oishi JS, et al. (1995) Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr 10: 366-373.
22. Forrester JE, Spiegelman D, Woods M, Knox TA, Fauntleroy JM, et al. (2001) Weight and body composition in a cohort of HIV-positive men and women. Public Health Nutr 4: 743-747.
23. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, et al. (2005) CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 41: 1662-1670.
24. Shor-Posner G, Campa A, Zhang G, Persaud N, Miguez-Burbano MJ, et al. (2000) When obesity is desirable: a longitudinal study of the Miami HIV-1- Infected Drug Abusers (MIDAS) cohort. J Acquir Immune Defic Syndr 23: 81-88.
25. Mallon PW, Miller J, Cooper DA, Carr A (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17: 971-979.
26. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
27. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, et al. (2004) AIDS Clinical Trial Group 892 Team. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 39: 1223-1230.
28. Flegal KM, Graubard BI, Williamson DF, Gail MH (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293: 1861-1867.
29. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162: 1867-1872.
30. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003) Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179-1193.
31. Friis-Møller N, Sabin CA, Weber R, Reiss P, El-Sadr WM, et al. (2003) Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
32. Dubé MP (2000) Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 31: 1467-1475.
33. Finkelstein EA, Fiebelkorn IC, Wang G (2003) National medical spending attributable to overweight and obesity: how much, and who's paying? Health Affairs: W3. pp 219-226.
34. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB (2003) Years of life lost due to obesity. JAMA 289: 187-193.
35. Shevitz AH, Knox TA (2001) Nutrition in the era of highly active antiretroviral therapy. Clin Infect Dis 32: 1769-1775.
36. Willett W, Dietz W, Colditz G (1999) Guidelines for healthy weight. N Engl J Med 341: 427-434.
37. Duran AC, Almeida LB, Segurado AA, Jaime PC (2008) Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet 21: 346-50.
38. Hendricks KM, Willis K, Houser R, Jones CY (2006) Obesity in HIV-infection: dietary correlates. J Am Coll Nutr 25: 321-31.
39. Jaime PC, Florindo AA, Latorre Mdo R, Segurado AA (2006) Central obesity and dietary intake in HIV/AIDS patients. Rev Saude Publica 40: 634-40.
40. Prentice AM, Jebb SA (2001) Beyond body mass index. Obes Rev 2: 141-7.